New findings from Seattle Children’s Research Institute’s Center for Clinical and Translational Research reveal that a three-dose primary series of Pfizer’s COVID-19 vaccine was safe and effective in children 6 months to 4 years of age, even when a new variant (Omicron) was circulating.
The findings were released on Feb. 16 in the New England Journal of Medicine by an international team conducting the study, including Seattle Children’s lead study investigator, Dr. Janet Englund.
